MSI-H/DMMR COLORECTAL CANCER
Clinical trials for MSI-H/DMMR COLORECTAL CANCER explained in plain language.
Never miss a new study
Get alerted when new MSI-H/DMMR COLORECTAL CANCER trials appear
Sign up with your email to follow new studies for MSI-H/DMMR COLORECTAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for aggressive colon cancer: targeted drug AK104 tested before surgery
Disease control Recruiting nowThis study tests a new drug called AK104 (Cadonilimab) given before and after surgery for people with a specific type of colon cancer (MSI-H/dMMR) that can be removed. The goal is to see if AK104 works better than standard chemotherapy at shrinking the tumor and preventing the ca…
Matched conditions: MSI-H/DMMR COLORECTAL CANCER
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated May 17, 2026 02:57 UTC
-
New drug combo aims to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called EIK1005, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the combination can shrink tumors. About 160 adults with certain ca…
Matched conditions: MSI-H/DMMR COLORECTAL CANCER
Phase: PHASE1, PHASE2 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated May 17, 2026 02:46 UTC